In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 544-549

  Bulik, Catharine C ^a   Tessier, Pamela R ^a   Keel, Rebecca A ^a   Sutherland, Christina A ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFUSION; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FEMALE; GENETIC VARIABILITY; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PHENOTYPE; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIGH;

EID: 84455169919     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01752-10     Document Type: Article

References (23)

1. Ambrose PG, Bhavnani SM, Jones RN. 2003. Pharmacokinetics- pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47:1643-1646. (Pubitemid 36548549)
2. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Beam TR, Jr. 1983. Recent developments in antimicrobial therapy with beta-lactam antibiotics. J. Med. 14:307-336.
4. Brown NP, Pillar CM, Sahm DF, Ge Y. 2009. Activity profile of CXA-101 and CXA-101/tazobactam against target gram-negative and gram-positive pathogens, abstr F1-1986. Abstr. 49th Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother.
5. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559.
6. Clinical and Laboratory Standards Institute. 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7 (26)2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Crandon JL, Kuti JL, Nicolau DP. 2009. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance. Ann. Pharmacother. 43:220-227.
8. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. 2009. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin. Ther. 31:2678-2688.
9. Gavin PJ, et al. 2006. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β- lactamase-producing Escherichia coli and Klebsiella species. Antimicrob. Agents Chemother. 50:2244-2247. (Pubitemid 43807556)
10. Jones RN, Kirby JT, Rhomberg PR. 2008. Comparative activity of meropenem in US medical centers (2007), initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis. 61:203-213. (Pubitemid 351680371)
11. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54:846-851.
12. Kim MK, et al. 2002. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 22: 569-577.
13. Komuro M, Kakuo H, Matsushita H, Shimada J. 1994. Inhibition of the renal excretion of tazobactam by piperacillin. J. Antimicrob. Chemother. 34:555-564. (Pubitemid 24344527)
14. López-Cerero L, et al. 2010. Comparative assessment of inoculum effects on the antimicrobial activity of amoxicillin-clavulanate and piperacillintazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates. Clin. Microbiol. Infect. 16:132-136.
15. Mattoes HM, et al. 2002. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375g q4hr and 4.5g q6hr. Chemotherapy 48:59-63. (Pubitemid 34507596)
16. Moya B, et al. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
17. Nicasio AM, Kuti JL, Nicolau DP. 2008. The current state of multidrug resistant Gram-negative bacilli in North America. Pharmacotherapy 28: 235-249.
18. Pagani L, et al. 1998. Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae. Chemotherapy 44:377-384. (Pubitemid 28468488)
19. Pitout JDD, Laupland KB. 2008. Extended-spectrum β-lactamase- producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. (Pubitemid 351249250)
20. Sykes RB, Bonner DP, Swabb EA. 1985. Modern β-lactam antibiotics. Pharm. Ther. 29:321-352.
21. Tam VH, et al. 2010. Prevalence, resistance mechanisms, and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:1160-1164.
22. Titelman E, Karlsson I, Ge Y, Giske CG. 2009. Activity of CXA-101 (CXA) plus tazobactam against ESBL-producing E. coli and K. pneumoniae, abstr. F1-1993. Abstr. 49th Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother.
23. Toda A, et al. 2008. Synthesis and SAR of novel parenteral antipseudomonal cephalosporins: discovery of FR264205. Bioorg. Med. Chem. Lett. 18:4849-4852.